STEM-21. CLINICAL RELEVANCE OF CANCER STEM CELL CYTOTOXICITY ASSAY IN GUIDING TREATMENT FOR GLIOBLASTOMA

BACKGROUND. The prognosis of glioblastoma (GBM) treated with standard-of-care regimens remains very poor with a median time to recurrence of 7-9 months, and a median survival of 15-18 months. GBMs contain a small, but resilient population of cancer stem cells (CSCs) that contribute to tumor initiati...

詳細記述

保存先:
書誌詳細
出版年:Neuro Oncol
主要な著者: Pier Paolo, Claudio, Ranjan, Tulika, Howard, Candace, Yu, Alexander, Xu, Linda, Aziz, Khaled, Jho, David, Leonardo, Jodi, Denning, Krista, Valluri, Jagan
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2020
主題:
Cancer Stem Cells
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651437/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.838
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料